Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BXLT's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

BXLT Guru Trades in

BXLT Guru Trades in

Q2 2016
2016

BXLT Guru Trades in 2016

Third Avenue Value Fund Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BXLT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Compare:XKRX:207940, NAS:REGN, XKRX:068270, NAS:ALXN, LSE:SHP, NAS:VRTX, NAS:INCY, XMCE:GRF.P, NAS:NKTR, HKSE:01177, SZSE:002252, XBRU:UCB, OCSE:NZYM B, NAS:BMRN, NAS:ALNY, OCSE:GEN, NAS:BIVV, HKSE:02269, NAS:JUNO, NAS:BLUE » details
Traded in other countries:9BX.Germany, BXLT.Mexico,
Headquarter Location:USA
Baxalta Inc is engaged in the developing and marketing of biopharmaceuticals. The Company offers biopharmaceuticals for the treatment of hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, and other chronic.

Baxalta Inc was incorporated on September 8, 2016. It is a biopharmaceutical company engaged in the field of unmet medical needs covering various diseases which includes haemophilia, immunology and oncology. The Company develops, manufactures and markets a diverse portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia. It also invests in emerging technology platforms, including gene therapy and biosimilars. Its competitors include Advate, Feiba, Gammagard. The Company is subject to rules and regulations put forth by the jurisdiction it operates in.

Ratios

vs
industry
vs
history

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.46
BXLT's Dividend Yield % is ranked lower than
77% of the 226 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. BXLT: 0.46 )
Ranked among companies with meaningful Dividend Yield % only.
BXLT' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.46
Current: 0.46
0
0.46
Dividend Payout Ratio 0.18
BXLT's Dividend Payout Ratio is ranked higher than
85% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. BXLT: 0.18 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BXLT' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.18
Current: 0.18
0
0.18
Forward Dividend Yield % 0.61
BXLT's Forward Dividend Yield % is ranked lower than
75% of the 221 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. BXLT: 0.61 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.46
BXLT's 5-Year Yield-on-Cost % is ranked lower than
81% of the 219 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. BXLT: 0.46 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BXLT' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.46
Current: 0.46
0
0.46

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $6,335.00
EPS (TTM) $ 1.21
52-Week Range $29.83 - 46.52
Shares Outstanding (Mil)683.54

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 6,653 7,364 7,990
EBIT (Mil $) 1,887 2,199 2,523
EBITDA (Mil $) 2,192 2,614 2,882
EPS ($) 1.95 2.42 2.82
EPS without NRI ($) 1.95 2.42 2.82
EPS Growth Rate
(Future 3Y To 5Y Estimate)
2.32%
Dividends per Share ($) 0.32 0.33 0.36

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}